Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

55.01 -1.15 (-2.06%)
Streaming Delayed Price Updated: 1:05 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
These rising drugmakers have serious arguments in their favor. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
These companies are in the early days of their growth stories. 
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Via Benzinga
Is It Too Late to Buy CRISPR Therapeutics Stock?
The biotech has been making a lot of noise since late last year. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects. 
Via The Motley Fool
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine. 
Via InvestorPlace
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
Each of these three companies are entering a new era of growth. 
Via The Motley Fool
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024
These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge. 
Via InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new 
Via Benzinga
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
The Top 3 Biotech Stocks to Buy in March 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors. 
Via InvestorPlace
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
The biotech company keeps moving closer to bringing its promising first gene therapy to market. 
Via The Motley Fool
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
This company's fortunes are likely to improve, and soon. 
Via The Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
3 Biotech Stocks Bound to Blast Off By 2029
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years. 
Via InvestorPlace
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Exposures Product Safety
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex shares have climbed almost 50% over the past year. 
Via The Motley Fool
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.